Meeting News

Pembrolizumab reduces mortality risk in advanced PD-L1-positive esophageal cancer

January 15, 2019
Pembrolizumab significantly improved OS compared with chemotherapy as second-line treatment for patients with advanced or metastatic esophageal or…
Feature

American Academy of Dermatology updates guidelines for primary cutaneous melanoma

January 11, 2019
The American Academy of Dermatology released new guidelines on melanoma treatment. The guidelines address areas such as melanoma in pregnancy and…

Roswell Park immunotherapy expert honored for melanoma research

January 11, 2019
Igor Puzanov, MD, MSCI, FACP, received the Melanoma Foundation Award for outstanding and lifelong

Nivolumab extends OS in advanced esophageal cancer

January 10, 2019
A randomized phase 3 trial designed to compare nivolumab with chemotherapy for patients with unresectable advanced or recurrent esophageal cancer met…

Avelumab fails to extend PFS in ovarian cancer

January 2, 2019
A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary…
Feature

NCI grant to fund study of CAR T-cell therapy for solid tumors

January 2, 2019
A $10.7 million grant from NCI will fund research at University of Pennsylvania’s Abramson Cancer Center to evaluate the use of chimeric…
Meeting News

Checkpoint inhibitors do not increase likelihood of fast lung cancer progression

December 28, 2018
Anti-PD-L1 therapy did not appear to be specifically associated with rapid tumor progression compared with chemotherapy among patients with…
FDA News

FDA approves Keytruda for Merkel cell carcinoma

December 19, 2018
The FDA today granted accelerated approval to pembrolizumab for adults and children with recurrent locally advanced or metastatic Merkel cell…

$name

Meeting News

Nivolumab safe, feasible with standard induction therapy for acute myeloid leukemia

December 19, 2018
SAN DIEGO — Adding nivolumab to induction therapy with idarubicin and cytarabine appeared to be a viable and safe treatment option for younger…